Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients

Table 3 Estimation of average treatment effects and potential outcome mean of RAAS treatment on death before ESRD by diabetic groups

Model for diabetic patients	Factors	RD	LL	UL	NNT	LL	UL
ATE	RAAS1 vs non-RAAS	0.030	−0.012	0.072	32.9	−12.6	78.5
	RAAS2 vs non-RAAS	−0.052	−0.069	−0.035	−19.1	−25.5	−12.9
		Risk	LL	UL	RR	LL	UL
POM	Non-RAAS	0.196	0.187	0.204
	RAAS1	0.227	0.186	0.268	1.155	0.939	1.369
	RAAS2	0.144	0.129	0.159	0.773	0.652	0.815
Model for non-diabetic patients	Factors	RD	LL	UL	NNT	LL	UL
ATE	RAAS1 vs non-RAAS	−0.009	−0.066	0.048	−113.6	−848.7	621.5
	RAAS2 vs non-RAAS	−0.064	−0.099	−0.029	−15.6	−24.2	−7.1
		Risk	LL	UL	RR	LL	UL
POM	Non-RAAS	0.223	0.215	0.229
	RAAS1	0.224	0.157	0.270	0.960	0.705	1.216
	RAAS2	0.159	0.124	0.193	0.713	0.557	0.868

ATE Average treatment effect, LL Lower limit, POM Potential outcome mean, RAAS1 Duration use of 0.25–1 year, RAAS2 Duration use of >1 year, RD Risk difference, RR Rate ratio, UL Upper limit

ISSN: 1471-2369